BIOMARKERS OF SARCOPENIA IN CLINICAL TRIALS RECOMMENDATIONS FROM THE INTERNATIONAL WORKING GROUP ON SARCOPENIA
CESARI M, FIELDING R, PAHOR M, GOODPASTER B, HELLERSTEIN M, ABELLAN VAN KAN G, ANKER S, RUTKOVE S, VRIJBLOED J, ISAAC M, ROLLAND Y, M’RINI C, AUBERTIN-LEHEUDRE M, CEDARBAUM J, ZAMBONI M, SIEBER C, LAURENT D, EVANS W, ROUBENOFF R, MORLEY J, VELLAS B. BIOMARKERS OF SARCOPENIA IN CLINICAL TRIALS RECOMMENDATIONS FROM THE INTERNATIONAL WORKING GROUP ON SARCOPENIA. The Journal Of Frailty & Aging 2012, 1-9. DOI: 10.14283/jfa.2012.17.Peer-Reviewed Original ResearchSkeletal muscle declineInternational Working GroupMuscle declineAge-related skeletal muscle declineBiomarkers of sarcopeniaClinical trial recommendationsSkeletal musclePublic health priorityAvailable biomarkersPotential great benefitAge-related modificationsClinical trialsTrial recommendationsHealth prioritySarcopeniaTherapeutic strategiesOlder personsWorking GroupOlder peopleBiomarkersMuscleSpecific recommendationsNegative outcomesGreat benefitGroup